Somewhat Favorable News Coverage Somewhat Unlikely to Affect Momenta Pharmaceuticals (NASDAQ:MNTA) Share Price

News coverage about Momenta Pharmaceuticals (NASDAQ:MNTA) has been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Momenta Pharmaceuticals earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.7954759924587 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of MNTA stock traded up $0.20 on Friday, hitting $26.50. 407,600 shares of the stock traded hands, compared to its average volume of 682,790. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -22.29 and a beta of 1.92. Momenta Pharmaceuticals has a twelve month low of $11.85 and a twelve month high of $32.20.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.50). The firm had revenue of $13.00 million for the quarter, compared to analyst estimates of $15.83 million. Momenta Pharmaceuticals had a negative net margin of 128.49% and a negative return on equity of 40.55%. The company’s revenue was down 44.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.50) EPS. analysts expect that Momenta Pharmaceuticals will post -2.06 EPS for the current fiscal year.

A number of research firms have issued reports on MNTA. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, August 1st. BidaskClub raised shares of Momenta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 14th. Cantor Fitzgerald set a $24.00 target price on shares of Momenta Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, August 9th. ValuEngine raised shares of Momenta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 2nd. Finally, TheStreet lowered shares of Momenta Pharmaceuticals from a “c-” rating to a “d” rating in a report on Tuesday, May 8th. Seven investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company’s stock. Momenta Pharmaceuticals has an average rating of “Buy” and an average price target of $17.38.

In related news, CEO Craig A. Wheeler sold 1,773 shares of the company’s stock in a transaction that occurred on Friday, August 10th. The stock was sold at an average price of $26.06, for a total value of $46,204.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Elizabeth Stoner sold 4,152 shares of the company’s stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $27.33, for a total value of $113,474.16. Following the completion of the transaction, the director now directly owns 33,791 shares of the company’s stock, valued at $923,508.03. The disclosure for this sale can be found here. Insiders have sold 103,668 shares of company stock worth $2,772,688 over the last quarter. Insiders own 4.80% of the company’s stock.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.

Read More: Average Daily Trade Volume – What It Means In Stock Trading

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply